



FOR IMMEDIATE RELEASE

Contact:
Abbey Madden
610-644-7000
abbeymadden@aquapharm.com

AQUA PHARMACEUTICALS WELCOMES KIMBERLEY FORBES-MCKEAN AS VICE PRESIDENT OF RESEARCH AND DEVELOPMENT

WEST CHESTER, Pa. – May 23, 2011 – West Chester-based Aqua Pharmaceuticals today announces the addition of Kimberley Forbes-McKean, Ph.D. as Vice President of Research and Development. In this role, Dr. Forbes-McKean will be responsible for oversight of research and development including project management, discovery, preclinical and clinical development, CMC, toxicology, regulatory affairs and quality assurance.

“Kimberley’s background in the biotech and pharmaceutical industry, with extensive experience in dermatological product development, will be a strong addition to the Aqua team,” said Jay Gooding, Aqua CEO. “Her unique perspective on our business strategy and objectives will no doubt lead to her contributing significantly to Aqua’s future success.”

Dr. Forbes-McKean brings over 20 years of experience in pharmaceutical development, and over 15 of those years have been in the area of dermatological drug and device development. Most recently, she was Executive Vice President and Chief Scientific Officer at Cutanea Life Sciences, Inc. since it was founded in 2005. Prior to Cutanea, Dr. Forbes-McKean was Senior Vice President and Chief Technical Officer at Isologen, Inc.; Vice President of Global Dermatological Product Development and Commercialization at Aventis Pharmaceutical, Inc.; and Worldwide Director of Dermatological Product Development at Dermik, Inc (a division of Aventis). In her role at Aventis/Dermik, she was primarily responsible for product development, project management, business development, regulatory and quality strategy, and her team was responsible for multiple product approvals leading to international commercialization of at least one new product each year. While there, she also created an independent project management department to focus on the development of dermatological products and portfolio management to provide strategic scientific direction and prioritize activities to meet the profit targets of the business unit.

Dr. Forbes-McKean holds a Ph.D. and an M.S. in analytical chemistry from the University of Massachusetts at Amherst, Mass., and a B.S. in chemistry from Union College in Schenectady, N.Y.

About Aqua Pharmaceuticals

West Chester, Pennsylvania-based Aqua Pharmaceuticals is a specialty pharmaceutical company focusing on acquiring, developing and marketing prescription dermatology products. Aqua is a portfolio company of Roundtable Healthcare Partners, an operations-oriented private equity firm that has raised \$1.9 billion in private equity funds and has invested more than \$250 million in capital over the past year in healthcare-related transactions. For more information, visit www.aquapharm.com.

###